mohammad jahanzeb, md, facp, on immunotherapy and treatment of metastatic breast cancer
Published 7 years ago • 114 plays • Length 1:29
Download video MP4
Download video MP3
Similar videos
-
0:35
mohammad jahanzeb, md, facp on the role of cdk inhibitors and their evolving role in breast cancer
-
0:48
mohammad jahanzeb, md, facp talks about impact of cdk4/6 inhibition added to letrozole
-
1:24
nci minute: immunotherapy for metastatic breast cancer
-
0:32
mohammad jahanzeb, md, facp speaks about testing for pd-l1 in the first-line nsclc setting
-
1:26
mohammad jahanzeb, md, facp, on the impact of the aphinity study presented at asco
-
2:58
patients reportedly beating cancer with just one tablet a day | 9 news australia
-
5:26
how does chemotherapy work? - hyunsoo joshua no
-
2:54
chemo side effects after my first treatment cancer vlog #6 september 6, 2022
-
1:03
dr. jahanzeb on the future of adjuvant therapy in her2 breast cancer
-
1:02
dr. mohammad jahanzeb on neratinib and trastuzumab in her2-positive breast cancer
-
1:28
mohammad jahanzeb, md, facp, discusses the results of the monarch-2 study presented at asco
-
2:00
phase ii study of bria-imt in metastatic breast cancer
-
4:27
study of immunotherapy combinations for patients with her2-positive metastatic breast cancer
-
1:56
dr. jahanzeb on eligibility criteria for immunotherapy trials in nsclc
-
0:34
future role of immunotherapy in her2 breast cancer
-
4:15
immunotherapy successfully treats advanced breast cancer
-
1:49
dr. jahanzeb on immunotherapy in elderly patients with nsclc
-
7:50
special issue on “immunotherapy of cancer: future possible therapy for metastatic cancer”
-
1:41
mohammad jahanzeb, md, facp, discusses the impact of keynote 189 & 42 on drug sequencing regimens
-
1:09
mohammad jahanzeb, md, facp, on the results of keynote 189, pdl-1 expression and patient selection
-
2:06
dr. jahanzeb on the aphinity and extenet trials in breast cancer
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
Clip.africa.com - Privacy-policy